Oncimmune (LON:ONC) Shares Up 4.7% – Here’s What Happened

Shares of Oncimmune Holdings plc (LON:ONC) shot up 4.7% during mid-day trading on Monday . The stock traded as high as GBX 4.50 ($0.06) and last traded at GBX 4.50 ($0.06). 752,922 shares were traded during mid-day trading, an increase of 79% from the average session volume of 421,424 shares. The stock had previously closed at GBX 4.30 ($0.05).

Oncimmune Stock Down 2.5 %

The company has a market cap of £4.42 million, a price-to-earnings ratio of 0.44 and a beta of 1.19. The company has a current ratio of 1.14, a quick ratio of 0.63 and a debt-to-equity ratio of -412.06. The firm’s fifty day moving average price is GBX 12.49 and its 200-day moving average price is GBX 14.65.

Oncimmune (LON:ONC) last posted its quarterly earnings data on Monday, February 10th. The company reported GBX (4.72) (($0.06)) EPS for the quarter. Oncimmune had a net margin of 581.63% and a negative return on equity of 2,277.74%.

About Oncimmune

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.